Research library

D

grade

Thymosin Alpha-1 has been studied mainly as an adjunctive therapy in cancer care, but the evidence is largely based on observational studies with inconsistent safety reporting.

Not reported in abstract.

summary

C

grade

This study identifies new antimicrobial peptides in Nile tilapia that respond to bacterial infection, expanding the understanding of fish immunity.

Not reported in abstract.

summary

C

grade

Thymosin β4 appears to reduce cell death and inflammatory markers in BV2 microglial cells subjected to pyroptosis, but its clinical relevance in humans is not established.

Not reported in abstract.

summary

C

grade

TB-500 showed a significant biomechanical advantage in Achilles tendon healing in rats, while BPC-157 did not demonstrate statistically significant improvements. Further studies are needed to explore their potential in human tendon repair.

Higher maximum load to failure in the TB-500 group compared to controls, p < 0.05.

summary

B

grade

Thymosin α1 may enhance immune responses against HIV-1, but findings are based on in vitro studies and limited to immunological responders.

Reduction of HIV-1 integrated DNA levels, p=0.012.

summary

B

grade

Thymosin α1 stimulation in vitro enhances immune responses in CD8+ T cells and reduces HIV reservoir size, but these findings need further investigation in clinical settings.

Intracellular p24 levels in CD4+ T cells decreased significantly, p=0.002.

summary

D

grade

Not reported in abstract.

summary

B

grade

Thymosin α1 does not correct the F508del-CFTR defect in human airway epithelial cells, indicating it may not be a viable treatment option for this cystic fibrosis mutation.

summary

A

grade

Thymosin α1 did not show a significant reduction in 28-day mortality for adults with sepsis, with a hazard ratio of 0.99, indicating no clear benefit.

28-day all-cause mortality: 23.4% (127/542) in thymosin α1 group vs 24.1% (132/547) in placebo group, hazard ratio 0.99, 95% CI 0.77 to 1.27, P=0.93.

summary

B

grade

Higher levels of urinary A1M and B2M are associated with an increased risk of cardiovascular death, but the clinical implications of these findings require further investigation.

1-SD higher urine A1M associated with HR 1.33 (95% CI 1.12-1.58) for cardiovascular death.

summary

B

grade

This study identifies potential circulating biomarkers for stage 1 hypertension using advanced machine learning techniques, but these findings require further validation.

AUROC = 0.7985 for CatBoost classifier.

summary

B

grade

The study indicates that a structured 3-tier triage model can improve patient throughput and accuracy during respiratory epidemics.

Mean daily patient throughput of 550.43 (SD ± 284.13) individuals.

summary

C

grade

Thymosin alpha 1 (Tα1) enhances CD8⁺ T-cell activation and may partially reverse exhaustion in vitro, but further in vivo studies are necessary to confirm these effects.

Not reported in abstract.

summary

B

grade

The combined measurement of fibrinogen and urinary alpha1-microglobulin may improve early risk assessment for respiratory tract infections in children with nephrotic syndrome.

AUC >0.917 for combined FIB and urinary alpha1-MG predictive accuracy.

summary

C

grade

Coho Salmon can reject copepodids after two days, which is linked to a strong immune response at the attachment sites. This response differs significantly from that of Atlantic Salmon.

Chum Salmon showed 30-40% mucous cell coverage compared to 10% in Atlantic Salmon.

summary

A

grade

Thymosin alpha 1 combined with sivelestat sodium and ambroxol showed a higher response rate and lower mortality in elderly patients with sepsis-associated ARDS, but further studies are needed to confirm these findings.

85.9% overall response rate in Tα1 group vs 72.1% in control, P<0.05

summary

B

grade

Thymosin alpha 1 combined with intravenous immunoglobulin may significantly reduce pulmonary adverse events in B-cell lymphoma patients receiving R-CHOP therapy, but further research is needed to confirm these findings.

13.0% vs. 31.7% overall PAE incidence, P < 0.001.

summary

B

grade

The study highlights that stop-loss mutations are enriched in cancer-related genes, but the implications for tumor behavior and patient outcomes are not yet clear.

3,757 stop-loss mutations identified in 3,249 different protein-coding genes.

summary

D

grade

Not reported in abstract.

summary

A

grade

Thymosin α1 may reduce 28-day mortality in sepsis patients, but its effectiveness varies among different subgroups, and further research is needed to confirm these results.

OR 0.73, 95%CI: 0.59-0.90, P = 0.003 for 28-day mortality reduction with Tα1.

summary

B

grade

Thymosin α1 combined with standard tuberculosis treatment may improve immune and pulmonary function in patients, but further studies are needed to confirm these findings.

FEV1, FVC, FEV1/FVC, and PEF were higher in the observation group compared to the control group (p < 0.05).

summary

C

grade

Thymosin α1 may influence inflammatory responses in pulpitis by inhibiting ferroptosis in dental pulp cells, but further research is needed to confirm these effects in humans.

Not reported in abstract.

summary